Showing 7 posts of 7 posts found.


GSK acquires oncology firm Tesaro for $5.1 billion

January 23, 2019
Research and Development Cancer, GSK, Tesaro, oncology, ovarian cancer

British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion). Tesaro, a Massachusetts-based clinical stage …

GSK to acquire oncology biotech Tesaro for $5.1 billion

December 3, 2018
Sales and Marketing GSK, GlaxoSmtihKline, Tesaro, acquisition, oncology, pharma

GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash …


New PARP inhibitor hits UK market, offering distinct advantage

December 18, 2017
Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical

Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …


Tesaro secures EU approval in specific ovarian cancer population

November 23, 2017
Sales and Marketing Europe, European Commission, Tesaro, Zejula, pharma

The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged.  Zejula is a poly (ADP-ribose) …


Tesaro’s ovarian cancer drug success threatens market rivals

October 12, 2016
Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib

Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …


Tesaro’s niraparib hits primary goal in late-stage trials for ovarian cancer trial; shares jump

June 30, 2016
Research and Development, Sales and Marketing Tesaro, drug trial, niraparib, ovarian cancer

Shares in Tesaro (Nasdaq: TSRO) jumped to more than double after the company reported late-stage trials for its drug to …


Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million

April 6, 2016
Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research

Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …

Latest content